Educational only — not medical advice, not a diagnosis. This page describes what users commonly discuss with their licensed healthcare provider around this topic. We do not diagnose, treat, cure, reverse, or fix any condition. No compound listed is recommended. Work with a licensed clinician for any decision.

Home/Conditions/Insulin Resistance

METABOLIC — EDUCATIONAL GUIDE

Insulin Resistance

The metabolic pattern where cells become less responsive to insulin - trackable through specific biomarkers before it becomes diabetes.

What This Is

Insulin resistance is the earliest detectable phase of metabolic dysfunction - years or decades before fasting glucose creeps up or HbA1c crosses the prediabetic line. It manifests as rising fasting insulin, rising triglycerides, dropping HDL-C, and eventually visceral fat accumulation. The HOMA-IR calculation (fasting insulin × fasting glucose / 405) gives a single-number insulin-sensitivity index.

Clinically, insulin resistance sits upstream of type 2 diabetes, cardiovascular disease, fatty liver disease, and cognitive decline. A formal diagnosis of diabetes or prediabetes requires specific criteria a licensed provider applies. The lab panel below is the set of markers commonly pulled when discussing metabolic health with a clinician - it is NOT a diagnostic framework.

Dietary patterns (refined carb load, meal timing), physical activity (resistance training + zone 2 cardio), and sleep quality are the lifestyle-modifiable levers consistently shown in clinical literature. Pharmacologic options are a separate conversation with your provider.

Biomarkers Users Commonly Track

The following lab markers are commonly discussed with a licensed provider in this context. They are not a diagnostic checklist. Only your clinician can interpret what these values mean for your specific situation.

Fasting Insulin<10 mIU/L · ideally 2–6 mIU/L for metabolic optimization

Earliest detectable marker of declining insulin sensitivity - moves years before glucose.

Fasting Glucose70–89 mg/dL is the metabolic-optimization target

Standard glycemic marker - less sensitive than fasting insulin but widely available.

HbA1c<5.4% (metabolic optimization target)

~90-day average glucose. Rises later than fasting insulin.

Triglycerides<100 mg/dL · ideal <80 mg/dL fasting

Atherogenic-dyslipidemia pattern marker. Rises with insulin resistance.

HDL-C50–80 mg/dL - extremely high levels (>90) carry their own concerns

Tends to drop as insulin resistance develops.

SHBG25–55 nmol/L is a common optimization target in men

Low SHBG in men often reflects insulin resistance independent of other markers.

ALT<25 U/L is a common metabolic-optimization target

Rises with hepatic fat accumulation - a downstream effect of insulin resistance.

Compounds Users Research (Ask Your Clinician)

No compound below is a recommended treatment. These are research-stage or investigational compounds that users commonly look up in this context. Any decision about their use is a conversation with a licensed healthcare provider, under their supervision, with full understanding of risks and your personal history.

Semaglutide

GLP-1 receptor agonist - users researching metabolic optimization discuss this with their clinician.

Tirzepatide

Dual GIP/GLP-1 agonist. Same class, different mechanism than semaglutide - worth understanding before a provider conversation.

MOTS-c

Mitochondrial peptide with research interest in insulin sensitivity - research-stage, discuss with your clinician.

Head-to-Head Compound Comparisons

Informational comparisons only - not endorsements. Users researching this condition often compare these compounds side by side when preparing to discuss options with their licensed provider.

Semaglutide vs Tirzepatide

Users researching GLP-class therapy for metabolic or weight-management goals with their provider.

Related Conditions

Metabolic Syndrome Elevated Visceral Fat

Bring the data to your next visit.

MyProtocolStack lets you log the biomarkers on this page across lab draws, chart the trend, and hand a structured report to your clinician. Better conversations start with better data. We do not replace your provider; we help you show up prepared.

Start tracking free →

Compliance notice: This page is informational and educational only. MyProtocolStack does not provide medical advice, diagnosis, or treatment. All references to biomarkers are educational. All references to compounds describe what users research and typically discuss with their clinician — not endorsements or treatment recommendations. Reference ranges vary by laboratory. Symptom interpretation and any protocol decisions require a licensed healthcare provider. If you are experiencing symptoms, consult your clinician.